Compare VTGN & USEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTGN | USEA |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3M | 21.7M |
| IPO Year | 2014 | 2022 |
| Metric | VTGN | USEA |
|---|---|---|
| Price | $0.24 | $2.65 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $0.90 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 42.7K |
| Earning Date | 06-16-2026 | 05-21-2026 |
| Dividend Yield | N/A | ★ 11.22% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | $5.55 |
| Revenue Next Year | $353.99 | $4.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $1.42 |
| 52 Week High | $5.14 | $2.82 |
| Indicator | VTGN | USEA |
|---|---|---|
| Relative Strength Index (RSI) | 35.18 | 52.59 |
| Support Level | $0.20 | $2.50 |
| Resistance Level | $0.65 | $2.69 |
| Average True Range (ATR) | 0.01 | 0.11 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 51.75 | 50.00 |
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.